Clareo Health | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Physician-diagnosed asthma requiring treatment with medium- to high-dose ICS-LABA for at least 12 months prior to screening.
Pre-BD FEV1 \< 80% predicted according to central over read value at Visit 2.
Documented historical post-BD reversibility of FEV1 ≥ 12% and ≥ 200 mL in FEV1.
At least 2 documented asthma exacerbations (requiring treatment with systemic CS, hospitalization, or emergency department visit) within 12 months prior to screening but not within the past 4 weeks prior to screening
ACQ-6 ≥ 1.5 at screening.
You may not be if
Maintenance use of asthma controllers other than ICS-LABA.
Have undergone bronchial thermoplasty.
Current smokers or participants with a smoking history of ≥ 10 pack-years and participants using vaping products, including electronic cigarettes.
Women who are pregnant (or who are considering pregnancy) or breastfeeding.
Current conditions or history of other diseases, as follows:
Clinically important pulmonary disease other than asthma ,Thrombocytopenia, coagulopathy, or platelet dysfunction.
Venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, moderate to severe heart failure (NYHA Class III or IV), cerebrovascular accident, myocardial infarction, coronary stenting, or CABG surgery.
Diagnosis of other significant cardiovascular diseases, including but not limited to angina, peripheral arterial disease, or uncontrolled arrhythmias such as atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, and forms of carditis.
Recipient of an organ transplant that requires continued immunosuppression.
